Asfotase alfa, a human recombinant tissue-nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein with enzymatic activity, promotes mineralisation of the skeleton in patients with hypophosphatasia.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Asfotase alfa is the active ingredient of these drugs:
Austria Brazil Canada Estonia Finland
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):